TYMS and neoplasm: The clinical influence of TS polymorphism in 5-FU based chemotherapy are often controversial because of different clinical settings (adjuvant vs. palliative), tumor type (colon vs. gastric cancer), and different 5-FU infusion times [16,25,26,39,42-45].